

San Antonio Breast Cancer Symposium

Henry B. Gonzalez Convention Centre

December 5-9, 2023

Abstracts

CCTG MA.27 – A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer

Time: December 6, 2023; 12:00-2:00 PM CT

Type: Poster

Session: Poster Session 1

Abstract: **Adjunctive statistical standardization of quantitated machine image analysis of Estrogen and Progesterone Receptors: CCTG MA.27 trial.**

Abstract #: PO1-27-10

Authors: Chapman JA, Bayani J, SenGupta S, Bartlett JMS, Piper T, Quintayo MA, Virk S, Goss P, Ingle J, Ellis M, Sledge Jr G, Budd G, Rabaglio M, Ansari R, Tozer R, D'Souza D, Chalchal H, Spadafora S, Stearns V, Perez EA, Gelmon K, Whelan T, Elliott C, Shepherd L, Chen B, Taylor K

Page #: 65 of the online Posters Session 1 program

CCTG MA.28/NCCTG N9831 – Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment For Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer

Time: December 7, 2023; 5:00-7:00 PM CT

Type: Poster

Session: Poster Session 4

Abstract: **MHC Class I and II Expression, Functional Tertiary Lymphoid Structure (TLS), and Outcomes in Early-Stage HER2-Positive (HER2+) Breast Cancer in NCCTG N9831 (Alliance)**

Abstract #: PO4-25-04

Authors: Chumsri S, Shachner T, Li Z, Norton N, Moreno-Aspitia A, Colon-Otero G, Perez E, Nassar A, Thompson E, Knutson K

Page #: 60 of the online Posters Session 4 program

CCTG MA.37/BIG 14-03 – PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Time: December 6, 2023; 12:00-2:00 PM CT

Type: Poster

Session: Poster Session 1

Abstract: **The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive, HER2-negative, early breast cancer: an exploratory analysis of the PALLAS study**

Abstract #: PO1-01-08

Authors: Agostinetti E, Pfeiler G, Hlauschek D, Mayer E, Lambertini M, de Azambuja E, Bellet- Ezquerra M, Meisel J, Rubovszky G, Zdenkowski N, Novik Y, Ruíz-Borrego M, Gelmon K, Mamounas E, Iwata H, Lu D, Sölkner L, Fesl C, Gnant M, DeMichele A

Page #: 3 of the online Posters Session 1 program

CCTG MA.37/BIG 14-03 – PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Time: December 6, 2023; 12:00-2:00 PM CT

Type: Poster

Session: Poster Session 1

Abstract: **Clinical characterization, prognostic and predictive values of HER2-low in early breast cancer in the PALLAS trial**

Abstract #: PO1-01-13

Authors: Nader-Marta G, Singer CF, Hlauschek D, DeMichele A, Tarantino P, Pfeiler G, Martín M, Balko J, Nowecki Z, Balic M, Brufsky A, Chan A, Morris PG, Haddad T, Loibl S, Y Liu, Sölkner L, Fesl C, Mayer E, Gnant M

Page #: 4 of the online Posters Session 1 program

CCTG MA.37/BIG 14-03 – PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Time: December 7, 2023; 12:00-2:00 PM CT

Type: Poster

Session: Poster Session 3

Abstract: **Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05)**

Abstract #: PO3-02-05

Authors: Kantor O, Fayanju O, Dueck A, Gnant M, Burstein H, Goetz M, Isaacs C, Shepherd L, Hahn O, Anderson D, Miller K, Rugo H, Traina T, Dayao Z, Clifton K, Winer E, Wolff A, Wolmark N, Lu D, O'Brien P, Scovil S, DeMichele A, Mayer E

Page #: 4 of the online Posters Session 3 program

CCTG MA.37/BIG 14-03 – PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Time: December 8, 2023; 8:15-11:15 AM CT

Type: Poster

Session: General Session 3

Abstract: **Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer**

Abstract #: GS03-07

Authors: Stover D, Hlauschek D, Mayer E, Symmans WF, Watson M, Barozzi I, Filipits M, Ballman K, Bellet-Ezquerria M, Balko J, Rubovszky G, Zdenkowski N, Brufsky A, Steger G, Isaacs C, Loibl S, Henao F, Regan M, Liu Y, Fesl C, O'Brien P, DeMichele A, Gnant M, Metzger O.

Page #: 12 of the online General Sessions program

CCTG MAC.18/Alliance A221405 – POSITIVE: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

Time: December 6, 2023; 8:15-11:15 AM CT

Type: Oral

Session: General Session 2

Abstract: **Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy**

Abstract #: GS02-11

Authors: Azim H, Niman S, Partridge A, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal A, Kroep J, Mailliez A, Warner E, Borges V, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Eon Lee J, Walshe J, Ruiz-Borrego M, Moore H, Saunders C, Bjelic-Radicic V, Susnjar S, Cardoso F, Klar N, Spanic T, Ruddy K, Piccart M, Korde L, Goldhirsch A, Gelber R, Pagani O, Peccatori FA

Page #: 9 of the online General Sessions program

CCTG MAC.28 – A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer (DEBRA)

Time: December 6, 2023; 12:00-2:00 PM CT

Type: Poster

Session: Poster Session 1

Abstract: **A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤ 18 breast cancer: NRG-BR007**

Abstract #: PO1-19-02

Authors: White J, Cecchini R, Harris E, Mamounas E, Stover D, Ganz P, Jaggi R, Anderson S, Bergom C, Théberge V, El-Tamer M, Zellars R, Shumway E, Chen GP, Julian T, Wolmark N

Page #: 49 of the online Posters Session 1 program

CCTG MAC.29/Alliance A012103 – OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Time: December 7, 2023; 5:00-7:00 PM CT

Type: Poster

Session: Poster Session 4

Abstract: **OptimICE-pCR: De-escalation of therapy in early-stage TNBC patients who achieve pCR after neoadjuvant chemotherapy with checkpoint inhibitor therapy (Alliance A012103)**

Abstract #: PO4-19-05

Authors: Tolaney S, Ballman K, Perou CM, Cescon D, Gatti-Mays M, Blinder V, Rosenberg S, Mittendorf E, Weiss A, Rugo H, Ho A, Casey D, Singh B, Smieliauskas F, Abdou Y, Damarla V, Meisel J, Carey L, Partridge A

Page #: 49 of the online Posters Session 4 program
